Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
12 08 2021
Historique:
received: 23 03 2021
accepted: 29 07 2021
entrez: 13 8 2021
pubmed: 14 8 2021
medline: 14 8 2021
Statut: epublish

Résumé

Malaria parasite transmission to mosquitoes relies on the uptake of sexual stage parasites during a blood meal and subsequent formation of oocysts on the mosquito midgut wall. Transmission-blocking vaccines (TBVs) and monoclonal antibodies (mAbs) target sexual stage antigens to interrupt human-to-mosquito transmission and may form important tools for malaria elimination. Although most epitopes of these antigens are considered highly conserved, little is known about the impact of natural genetic diversity on the functional activity of transmission-blocking antibodies. Here we measured the efficacy of three mAbs against leading TBV candidates (Pfs48/45, Pfs25 and Pfs230) in transmission assays with parasites from naturally infected donors compared to their efficacy against the strain they were raised against (NF54). Transmission-reducing activity (TRA) was measured as reduction in mean oocyst intensity. mAb 45.1 (α-Pfs48/45) and mAb 4B7 (α-Pfs25) reduced transmission of field parasites from almost all donors with IC

Identifiants

pubmed: 34385463
doi: 10.1038/s41541-021-00366-9
pii: 10.1038/s41541-021-00366-9
pmc: PMC8361195
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101

Subventions

Organisme : RCUK | Medical Research Council (MRC)
ID : MR/R015600/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/R015600/1
Organisme : Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)
ID : 192.061

Informations de copyright

© 2021. The Author(s).

Références

World Health Organization. World Malaria Report (WHO, 2019).
Rabinovich, R. N. et al. malERA: an updated research agenda for malaria elimination and eradication. PLoS Med. 14, e1002456 (2017).
pubmed: 29190300 pmcid: 5708604 doi: 10.1371/journal.pmed.1002456
Sinden, R. E. The cell biology of sexual development in plasmodium. Parasitology 86, 7–28 (1983). Pt 4.
pubmed: 6191269 doi: 10.1017/S0031182000050824
Sinden, R. E. Sexual development of malarial parasites. Adv. Parasitol. 22, 153–216 (1983).
pubmed: 6141715 doi: 10.1016/S0065-308X(08)60462-5
Meis, J. F., Wismans, P. G., Jap, P. H., Lensen, A. H. & Ponnudurai, T. A scanning electron microscopic study of the sporogonic development of Plasmodium falciparum in Anopheles stephensi. Acta Trop. 50, 227–236 (1992).
pubmed: 1348599 doi: 10.1016/0001-706X(92)90079-D
Vermeulen, A. N. et al. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 162, 1460–1476 (1985).
pubmed: 2865324 doi: 10.1084/jem.162.5.1460
Quakyi, I. A. et al. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 139, 4213–4217 (1987).
pubmed: 2447164
Rener, J., Graves, P. M., Carter, R., Williams, J. L. & Burkot, T. R. Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum. J. Exp. Med. 158, 976–981 (1983).
pubmed: 6350527 doi: 10.1084/jem.158.3.976
Carter, R. et al. Target antigens in malaria transmission blocking immunity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 307, 201–213 (1984).
pubmed: 6151684 doi: 10.1098/rstb.1984.0120
Talaat, K. R. et al. Safety and immunogenicity of Pfs25-EPA/Alhydrogel(R), a transmission blocking vaccine against Plasmodium falciparum: an open label study in malaria naive adults. PLoS ONE 11, e0163144 (2016).
pubmed: 27749907 pmcid: 5066979 doi: 10.1371/journal.pone.0163144
Wu, Y. et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3, e2636 (2008).
pubmed: 18612426 pmcid: 2440546 doi: 10.1371/journal.pone.0002636
Chichester, J. A. et al. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a phase 1 dose-escalation study in healthy adults. Vaccine 36, 5865–5871 (2018).
pubmed: 30126674 pmcid: 6143384 doi: 10.1016/j.vaccine.2018.08.033
Sagara, I. et al. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. Lancet Infect. Dis. 18, 969–982 (2018).
pubmed: 30061051 pmcid: 6287938 doi: 10.1016/S1473-3099(18)30344-X
Healy, S. A. et al. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J. Clin. Invest. https://doi.org/10.1172/JCI146221 (2021).
de Jong, R. M. et al. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites. Immunol. Rev. 293, 190–215 (2020).
pubmed: 31840844 doi: 10.1111/imr.12828
Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635–659 (2016).
pubmed: 27168247 pmcid: 6034635 doi: 10.1146/annurev-immunol-041015-055515
Wang, X., Mathieu, M. & Brezski, R. J. IgG Fc engineering to modulate antibody effector functions. Protein Cell 9, 63–73 (2018).
pubmed: 28986820 doi: 10.1007/s13238-017-0473-8
Ellis, R. D., Sagara, I., Doumbo, O. & Wu, Y. Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum. Vaccin 6, 627–634 (2010).
pubmed: 20519960 pmcid: 3056062 doi: 10.4161/hv.6.8.11446
Niederwieser, I., Felger, I. & Beck, H. P. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am. J. Trop. Med Hyg. 64, 9–11 (2001).
pubmed: 11425169 doi: 10.4269/ajtmh.2001.64.9
Roeffen, W. et al. Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen. Exp. Parasitol. 97, 45–49 (2001).
pubmed: 11207113 doi: 10.1006/expr.2000.4586
Roeffen, W. et al. Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs. Exp. Parasitol. 80, 15–26 (1995).
pubmed: 7529717 doi: 10.1006/expr.1995.1003
Roeffen, W. et al. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent. Infect. Immun. 63, 467–471 (1995).
pubmed: 7822011 pmcid: 173018 doi: 10.1128/iai.63.2.467-471.1995
Barr, P. J. et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174, 1203–1208 (1991).
pubmed: 1940798 doi: 10.1084/jem.174.5.1203
Miura, K. et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS ONE 8, e57909 (2013).
pubmed: 23483940 pmcid: 3590281 doi: 10.1371/journal.pone.0057909
Churcher, T. S. et al. Measuring the blockade of malaria transmission–an analysis of the standard membrane feeding assay. Int. J. Parasitol. 42, 1037–1044 (2012).
pubmed: 23023048 doi: 10.1016/j.ijpara.2012.09.002
Sauerwein, R. W. & Bousema, T. Transmission blocking malaria vaccines: Assays and candidates in clinical development. Vaccine 33, 7476–7482 (2015).
pubmed: 26409813 doi: 10.1016/j.vaccine.2015.08.073
Grignard, L. et al. Transmission of molecularly undetectable circulating parasite clones leads to high infection complexity in mosquitoes post feeding. Int. J. Parasitol. 48, 671–677 (2018).
pubmed: 29738740 pmcid: 6018601 doi: 10.1016/j.ijpara.2018.02.005
MalariaGEN et al. An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Res. 6, 42 https://doi.org/10.12688/wellcomeopenres.16168.2 (2021).
Aurrecoechea, C. et al. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 37, D539–D543 (2009).
pubmed: 18957442 doi: 10.1093/nar/gkn814
Kundu, P. et al. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45. Nat. Commun. 9, 4458 (2018).
pubmed: 30367064 pmcid: 6203815 doi: 10.1038/s41467-018-06742-9
Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408–416 (2018).
pubmed: 29554083 pmcid: 5893371 doi: 10.1038/nm.4512
Hooft van Huijsduijnen, R. et al. Reassessing therapeutic antibodies for neglected and tropical diseases. PLoS Negl. Trop. Dis. 14, e0007860 (2020).
pubmed: 31999695 pmcid: 6991954 doi: 10.1371/journal.pntd.0007860
Conway, D. J. et al. Extreme geographical fixation of variation in the Plasmodium falciparum gamete surface protein gene Pfs48/45 compared with microsatellite loci. Mol. Biochem. Parasitol. 115, 145–156 (2001).
pubmed: 11420101 doi: 10.1016/S0166-6851(01)00278-X
Kapulu, M. C. et al. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Sci. Rep. 5, 11193 (2015).
pubmed: 26063320 pmcid: 4463016 doi: 10.1038/srep11193
Da, D. F. et al. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds. Infect. Immun. 81, 1984–1989 (2013).
pubmed: 23509152 pmcid: 3676035 doi: 10.1128/IAI.00016-13
Bompard, A. et al. Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations. Sci. Rep. 7, 6766 (2017).
pubmed: 28754921 pmcid: 5533793 doi: 10.1038/s41598-017-06130-1
MacDonald, N. J. et al. Structural and immunological characterization of recombinant 6-cysteine domains of the Plasmodium falciparum sexual stage protein Pfs230. J. Biol. Chem. 291, 19913–19922 (2016).
pubmed: 27432885 pmcid: 5025679 doi: 10.1074/jbc.M116.732305
Stone, W., Bousema, T., Sauerwein, R. & Drakeley, C. Two-faced immunity? The evidence for antibody enhancement of malaria transmission. Trends Parasitol. 35, 140–153 (2019).
pubmed: 30573175 doi: 10.1016/j.pt.2018.11.003
Coelho, C. H. et al. A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes. Nat. Commun. 12, 1750 (2021).
pubmed: 33741942 pmcid: 7979743 doi: 10.1038/s41467-021-21955-1
McLeod, B. et al. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25. Nat. Commun. 10, 4328 (2019).
pubmed: 31551421 pmcid: 6760140 doi: 10.1038/s41467-019-11980-6
Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165–173 (1989). Pt 2.
pubmed: 2668861 pmcid: 2668861 doi: 10.1017/S0031182000062065
Delemarre-van de Waal, H. A. & de Waal, F. C. [A 2d patient with tropical malaria contracted in a natural way in the Netherlands]. Ned. Tijdschr. Geneeskd. 125, 375–377 (1981).
pubmed: 7012644
Teirlinck, A. C. et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J. Infect. Dis. 207, 656–660 (2013).
pubmed: 23186785 doi: 10.1093/infdis/jis725
Graumans, W. et al. Plasmodium falciparum gametocyte enrichment in peripheral blood samples by magnetic fractionation: gametocyte yields and possibilities to reuse columns. Am. J. Trop. Med. Hyg. 100, 572–577 (2019).
pubmed: 30608048 pmcid: 6402936 doi: 10.4269/ajtmh.18-0773
Walk, J. et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial. BMC Med. 15, 168 (2017).
pubmed: 28903777 pmcid: 5598044 doi: 10.1186/s12916-017-0923-4
van de Vegte-Bolmer, M. et al. A portfolio of geographically distinct laboratory-adapted Plasmodium falciparum clones with consistent infection rates in anopheles mosquitoes. Preprint at https://doi.org/10.21203/rs.3.rs-565768/v1 (2021).
McCall, M. B. B. et al. Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers. Sci. Transl. Med. 9, eaag2490 (2017).
Stone, W. J. et al. The relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays. Sci. Rep. 3, 3418 (2013).
Bradley, J. et al. Predicting the likelihood and intensity of mosquito infection from sex specific Plasmodium falciparum gametocyte density. Elife 7, e34463 (2018).
Annan, Z., Durand, P., Ayala, F. J., Arnathau, C. & Awono-Ambene, P. et al. Population genetic structure of Plasmodium falciparum in the two main African vectors, Anopheles gambiae and Anopheles funestus. Proc. Natl Acad. Sci. USA 104, 7987–7992 (2007).
pubmed: 17470800 pmcid: 1876559 doi: 10.1073/pnas.0702715104
Singh, S. K., Thrane, S., Chourasia, B. K., Teelen, K. & Graumans, W. et al. Pfs230 and Pfs48/45 fusion proteins elicit strong transmission-blocking antibody responses against Plasmodium falciparum. Front. Immunol. 10, 1256 (2019).
pubmed: 31231386 pmcid: 6560166 doi: 10.3389/fimmu.2019.01256
Jaroszewski, L., Rychlewski, L., Li, Z., Li, W. & Godzik, A. FFAS03: a server for profile-profile sequence alignments. Nucleic Acids Res. 33, W284–W288 (2005).
pubmed: 15980471 pmcid: 1160179 doi: 10.1093/nar/gki418
Ranford-Cartwright, L. C., Balfe, P., Carter, R. & Walliker, D. Genetic hybrids of Plasmodium falciparum identified by amplification of genomic DNA from single oocysts. Mol. Biochem. Parasitol. 49, 239–243 (1991).
pubmed: 1775167 doi: 10.1016/0166-6851(91)90067-G
Gerloff, D. L., Creasey, A., Maslau, S. & Carter, R. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 102, 13598–13603 (2005).
pubmed: 16155126 pmcid: 1224620 doi: 10.1073/pnas.0502378102
Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004).
pubmed: 15173120 pmcid: 419797 doi: 10.1101/gr.849004
Madeira, F., Park, Y. M., Lee, J., Buso, N. & Gur, T. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47, W636–W641 (2019).
pubmed: 30976793 pmcid: 6602479 doi: 10.1093/nar/gkz268
Miller, R. H., Hathaway, N. J., Kharabora, O., Mwandagalirwa, K. & Tshefu, A. et al. A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity. Malar. J. 16, 490 (2017).
pubmed: 29246158 pmcid: 5732508 doi: 10.1186/s12936-017-2137-9
Hathaway, N. J., Parobek, C. M., Juliano, J. J. & Bailey, J. A. SeekDeep: single-base resolution de novo clustering for amplicon deep sequencing. Nucleic Acids Res. 46, e21 (2018).
pubmed: 29202193 doi: 10.1093/nar/gkx1201
RStan: the R interface to Stan v. R package version 2.18.2 (2018).
Rethinking: Statistical Rethinking Package v. R Package Version 1.59 (2016).
McElreath, R. Statistical Rethinking: A Bayesian Course with Examples in R and Stan (CRC Press, 2016).

Auteurs

Roos M de Jong (RM)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

Lisette Meerstein-Kessel (L)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Center for Molecular and Biomolecular Informatics, Radboud University Medical Center, Nijmegen, The Netherlands.

Dari F Da (DF)

Institut de Recherche en Sciences de la Santé, Direction Régionale, Bobo Dioulasso, Burkina Faso.

Sandrine Nsango (S)

Malaria Research Laboratory, OCEAC, Yaoundé, Cameroon.
Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.

Joseph D Challenger (JD)

Medical Research Council Centre for Global Infections Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Marga van de Vegte-Bolmer (M)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

Geert-Jan van Gemert (GJ)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

Elias Duarte (E)

EPPIcenter Research Program, Division of HIV, ID, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.

Noam Teyssier (N)

EPPIcenter Research Program, Division of HIV, ID, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.

Robert W Sauerwein (RW)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
TropIQ Health Sciences, Nijmegen, Netherlands.

Thomas S Churcher (TS)

Medical Research Council Centre for Global Infections Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Roch K Dabire (RK)

Institut de Recherche en Sciences de la Santé, Direction Régionale, Bobo Dioulasso, Burkina Faso.

Isabelle Morlais (I)

Malaria Research Laboratory, OCEAC, Yaoundé, Cameroon.
MIVEGEC, Université Montpellier, IRD, CNRS, Montpellier, France.

Emily Locke (E)

PATH's Malaria Vaccine Initiative, Washington, DC, USA.

Martijn A Huynen (MA)

Center for Molecular and Biomolecular Informatics, Radboud University Medical Center, Nijmegen, The Netherlands.

Teun Bousema (T)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. Teun.bousema@radboudumc.nl.

Matthijs M Jore (MM)

Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. Matthijs.jore@radboudumc.nl.

Classifications MeSH